Clinical trials: Phase 1
Dose Finding Study
Safety, Tolerability and Pharmacokinetics of Escalating Single Doses of TAK-828 in Healthy Participants
The purpose of this study is to evaluate the safety and tolerability of single oral doses of TAK-828 in healthy non-Japanese and Japanese participants.
- Trial name
- NCT02706834
- Testing
- TAK-828
- Where
- 2 sites in United States
- Volunteers
- 36 people, healthy volunteers welcome
- Sponsor
- Takeda
Food Effect, Healthy
A Food Effects Study and Optional Multi Dose Study to Assess PK of BTD-001
This is a single-centre, open-label study in healthy male and non-pregnant, non-lactating females. The study will consist of up to 2 parts; the decision to proceed to the optional second part will be made following review of Part…
- Trial name
- NCT03150498
- Testing
- BTD-001
- Where
- United Kingdom
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- Balance Therapeutics
Acute Lymphoblastic Leukemia
Liposomal Vincristine Plus Dexamethasone in Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia
The purpose of this study is to find the highest safe dose and to assess the anti-tumor effect of liposomal vincristine with dexamethasone in patients with relapsed or refractory acute lymphoblastic leukemia (ALL).
- Trial name
- NCT00144963
- Testing
- Vincristine Sulfate Liposomes Injection, Dexamethasone
- Where
- 3 sites in United States
- Volunteers
- 36 people
- Sponsor
- Acrotech Biopharma Inc.
Solid Tumors
A Phase I Pharmacologic Study of CYC116, an Oral Aurora Kinase Inhibitor, in Patients With Advanced Solid Tumors
This is a phase I study of an investigational cancer drug, CYC116, in patients with advanced solid tumors.
- Trial name
- NCT00560716
- Testing
- CYC116
- Where
- 2 sites in United States
- Volunteers
- 25 people
- Sponsor
- Cyclacel Pharmaceuticals, Inc.
Solid Tumor, Adult
A Phase l Study of By101298, an Oral DNA-PK Inhibitor, in Patients With Advanced Solid Tumors
BY101298 is an innovative DNA-dependent protein kinases (DNA-PK) highly selective small molecule inhibitor. DNA-dependent protein kinases (DNA-PK plays a key role in the NHEJ repair pathway to repair DNA double-strand breaks…
- Trial name
- NCT06462716
- Testing
- BY101298 Capsules
- Where
- China
- Volunteers
- 36 people
- Sponsor
- Chengdu Baiyu Pharmaceutical Co., Ltd.
FSHD, FSHD1
Phase 2 Open-label Extension Study of AOC 1020 in Participants With Facioscapulohumeral Muscular Dystrophy (FSHD)
A Phase 2 Open-label Extension Study to Evaluate the Long-Term Safety, Tolerability, and Efficacy of AOC 1020 Administered Intravenously to Participants with Facioscapulohumeral Muscular Dystrophy (FSHD)
- Conditions
- FSHD, FSHD1, FSHD2, FMD
- Trial name
- FORTITUDE-OLE (NCT06547216)
- Testing
- AOC 1020
- Where
- 17 sites in United States, Canada and 1 more
- Volunteers
- 84 people
- Sponsor
- Avidity Biosciences, Inc.
Advanced EGFR Positive Solid Tumor
ZZ06 in Adult Patients With Advanced Solid Tumor Malignancies
This is a Phase 1, Multicenter, Open-label study to assess the safety, tolerability and preliminary efficacy of ZZ06 in participants with all Adult Patients with Advanced EGFR-positive Solid Tumor Malignancies who are not able to…
- Trial name
- NCT04412616
- Testing
- ZZ06
- Where
- 5 sites in United States, China
- Volunteers
- 60 people
- Sponsor
- Changchun Intellicrown Pharmaceutical Co. LTD
Adenocarcinoma of Gastric, Adenocarcinoma of Esophagogastric Junction
Clinical Study of IM96 CAR-T Cell Therapy in Patients With Advanced Adenocarcinoma of Gastric/Esophagogastric Junction
This study, a single-center, open, single-dose clinical study, was designed to evaluate the safety and efficacy of IM96 CAR-T cells in treating patients with advanced adenocarcinoma of gastric/esophagogastric junction
- Trial name
- NCT07406984
- Testing
- IM96 CAR-T Cells
- Where
- China
- Volunteers
- 18 people
- Sponsor
- Beijing Immunochina Medical Science & Technology Co., Ltd.
N/A - Healthy Subjects
Phase 1 Drug Interaction Study of Apixaban and Atenolol in Healthy Subjects
The purpose of this study is to assess the effect of Atenolol 100 mg on the Pharmacokinetics (PK) of Apixaban and the effect of Apixaban 10 mg on the PK of Atenolol in Healthy subjects.
- Trial name
- NCT02262533
- Testing
- Apixaban, Atenolol
- Where
- United States
- Volunteers
- 15 people, healthy volunteers welcome
- Sponsor
- Bristol-Myers Squibb
Healthy
Dacomitinib (PF-00299804) Pharmacokinetics In Chinese Healthy Volunteers
As part of the global clinical development program for Dacomitinib, studies are planned in cancer patients in China. An assessment of Dacomitinib pharmacokinetics in Chinese subjects, as required by the Chinese Health…
- Trial name
- NCT02097433
- Testing
- Dacomitinib
- Where
- China
- Volunteers
- 14 people, healthy volunteers welcome
- Sponsor
- Pfizer
Healthy Participants Study
Phase I Clinical Study of ZL-65 Tablet in Healthy Adult Participants in China
To evaluate the tolerability and safety of a single oral dose of ZL-65 tablets in healthy adult trial participants through dose escalation; and to preliminarily assess the pharmacokinetic and pharmacodynamic characteristics of a…
- Trial name
- NCT07757152
- Testing
- This group of participants take ZL-65 tablet
- Where
- China
- Volunteers
- 108 people, healthy volunteers welcome
- Sponsor
- Chengdu Zenitar Biomedical Technology Co., Ltd
Healthy
A Study to Investigate the Safety, Tolerability, and Pharmacokinetics of PF-06649751 Co-administered With Trimethobenzamide Hydrochloride in Healthy Subjects
This study will test the hypothesis that PF-06649751 with continuous co-administration of trimethobenzamide hydrochloride (TMB) with will be safe and well tolerated.
- Trial name
- NCT02262767
- Testing
- PF-06649751, Trimethobenzamide Hydrochloride
- Where
- 2 sites in Belgium
- Volunteers
- 9 people, healthy volunteers welcome
- Sponsor
- Pfizer
Solid Malignancies, Hematologic Malignancies
A Phase 1 Study of IM-1021 in Participants With Advanced Cancer
IM-1021-101 is a Phase 1 study to determine the safety and effectiveness of IM-1021 in treating participants with advanced cancer.
- Trial name
- NCT06823167
- Testing
- IM-1021
- Where
- 24 sites in United States, Denmark and 2 more
- Volunteers
- 190 people
- Sponsor
- Immunome, Inc.
Peripheral Arterial Occlusive Disease
Pilot Study to Compare ISOVUE®-250 and VISIPAQUE™ 270 for Motion Artifact and Pain in Peripheral DSA
The purpose of this study is to compare ISOVUE-250 and VISIPAQUE 270 for motion artifact and pain following intraarterial injection for peripheral DSA.
- Trial name
- NCT00740207
- Testing
- VISIPAQUE 270, Isovue 250
- Volunteers
- 33 people
- Sponsor
- Bracco Diagnostics, Inc
Health Volunteers
Study To Evaluate The Effect Of Multiple Doses of CTP-543 On The Pharmacokinetics Of Single Doses of Midazolam In Healthy Subjects
This is a single center, Phase 1, open-label, fixed-sequence, drug-drug interaction study to determine the effect of CTP-543 on the pharmacokinetics (PK) of midazolam in healthy adult subjects
- Trial name
- NCT05467709
- Testing
- Midazolam, CTP-543
- Where
- United States
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Concert Pharmaceuticals
Ovarian Epithelial Cancer, Fallopian Tube Cancer
A Clinical Study of Gimatecan in Advanced Ovarian Epithelial Cancer, Fallopian Tube Cancer or Primary Peritoneal Cancer
This is a Phase 1, open-label, dose-escalation ,and multidose study, aiming to investigate the safety, tolerability and pharmacokinetics of Gimatecan in Advanced Ovarian Epithelial Cancer, Fallopian Tube Cancer or Primary…
- Conditions
- Ovarian Epithelial Cancer, Fallopian Tube Cancer, Primary Peritoneal Cancer
- Trial name
- NCT04029909
- Testing
- Gimatecan 0.6mg/m2/d, 0.8mg/m2/d, 0.4mg/m2/d
- Where
- China
- Volunteers
- 12 people
- Sponsor
- Lee's Pharmaceutical Limited
Waldenstrom's Macroglobulinemia
Phase 1/2 Dose Escalation Study in Patients With Relapsed or Refractory Waldenstrom's Macroglobulinemia
Recent reports have identified a specific oncogenic mutation L265P of the MYD88 gene in approximately 90% of the patients with Waldenström's macroglobulinemia.
- Trial name
- 8400-401 (NCT02092909)
- Testing
- IMO-8400
- Where
- 10 sites in United States
- Volunteers
- 31 people
- Sponsor
- Idera Pharmaceuticals, Inc.
Postoperative Pain
Study Evaluating the Safety, Efficacy and Pharmacokinetics of SYH9089 Injection in Patients Undergoing Abdominal Surgery.
This is a randomized, double-blind, active drug- and placebo-controlled, dose-escalation clinical study conducted in patients scheduled to undergo abdominal surgery.
- Trial name
- NCT07519109
- Testing
- SYH9089 injection, Ropivacaine hydrochloride, 0.9 % sodium chloride
- Where
- China
- Volunteers
- 60 people
- Sponsor
- CSPC Ouyi Pharmaceutical Co., Ltd.
Colorectal Carcinoma
Study of Pembrolizumab (MK-3475) as Monotherapy in Participants With Previously-Treated Locally Advanced Unresectable or Metastatic Colorectal Cancer (MK-3475-164/KEYNOTE-164)
In this study, participants with previously-treated locally-advanced unresectable or metastatic mismatched repair (MMR) deficient or microsatellite instability-high (MSI-H) colorectal carcinoma (CRC) will be treated with…
- Trial name
- NCT02460198
- Testing
- Pembrolizumab
- Volunteers
- 124 people
- Sponsor
- Merck Sharp & Dohme LLC
Solid Tumor
A Study of ZG005 Combined With Donafenib in Patients With Advanced Solid Tumor
This is a Multi-center, Open-labe, Phase I/II Study to evaluate the safety and tolerability of ZG005 Combined With Donafenib in Patients With Advanced Solid Tumor.
- Trial name
- NCT06239298
- Testing
- ZG005 Powder for Injection, Donafenib Tosilate Tablets
- Where
- China
- Volunteers
- 130 people
- Sponsor
- Suzhou Zelgen Biopharmaceuticals Co.,Ltd